PME shares: your next growth investment?

This article presents a valuation-focused overview of two Australian-listed equities: Pro Medicus Ltd (healthcare technology) and Rio Tinto Ltd (mining/materials). The piece frames both as potential growth investments for 2026, suggesting readers evaluate their respective valuations in the context of forward earnings and sector tailwinds.

Pro Medicus operates in medical imaging software and AI-driven diagnostic solutions, sectors with structural growth drivers from aging populations and healthcare digitalization. Rio Tinto's investment thesis centers on commodity cycles, capital discipline, and energy transition demand (particularly lithium and copper). The article does not present new catalysts, earnings surprises, or material corporate actions—it is a valuation methodology piece designed for retail investor education.

Neither ticker trades on US exchanges (both are ASX-listed), and the article contains no material news that would alter institutional positioning in US equities or broad market indices. The Australian equity focus and lack of actionable corporate developments limit direct correlation to S&P 500 momentum or sector rotation signals.

Sector implication: The mention of Rio Tinto implies commodities/mining exposure, while Pro Medicus reflects healthcare technology positioning. However, without catalyst-driven repricing or guidance changes, this remains educational commentary rather than market-moving analysis.